(-)-LariciresinolCAS# 83327-19-9 |
- Lariciresinol
Catalog No.:BCN5158
CAS No.:27003-73-2
- (±)-Lariciresinol
Catalog No.:BCN9662
CAS No.:105367-81-5
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 83327-19-9 | SDF | Download SDF |
| PubChem ID | 134203 | Appearance | Powder |
| Formula | C20H24O6 | M.Wt | 360.4 |
| Type of Compound | Lignans | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | 4-[[5-(4-hydroxy-3-methoxyphenyl)-4-(hydroxymethyl)oxolan-3-yl]methyl]-2-methoxyphenol | ||
| SMILES | COC1=C(C=CC(=C1)CC2COC(C2CO)C3=CC(=C(C=C3)O)OC)O | ||
| Standard InChIKey | MHXCIKYXNYCMHY-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C20H24O6/c1-24-18-8-12(3-5-16(18)22)7-14-11-26-20(15(14)10-21)13-4-6-17(23)19(9-13)25-2/h3-6,8-9,14-15,20-23H,7,10-11H2,1-2H3 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | 1. Lariciresinol administration can inhibit the tumor growth and tumor angiogenesis, conceivable importance of dietary lignan lariciresinol in inhibition of breast cancer development. |
| Targets | VEGFR |
(-)-Lariciresinol Dilution Calculator
(-)-Lariciresinol Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.7747 mL | 13.8735 mL | 27.7469 mL | 55.4939 mL | 69.3674 mL |
| 5 mM | 0.5549 mL | 2.7747 mL | 5.5494 mL | 11.0988 mL | 13.8735 mL |
| 10 mM | 0.2775 mL | 1.3873 mL | 2.7747 mL | 5.5494 mL | 6.9367 mL |
| 50 mM | 0.0555 mL | 0.2775 mL | 0.5549 mL | 1.1099 mL | 1.3873 mL |
| 100 mM | 0.0277 mL | 0.1387 mL | 0.2775 mL | 0.5549 mL | 0.6937 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- 8(17),13-Labdadien-15,16-olide
Catalog No.:BCN4374
CAS No.:83324-51-0
- Bryostatin 1
Catalog No.:BCC7343
CAS No.:83314-01-6
- 7-Hydroxycoumarin-6-carboxylic acid
Catalog No.:BCN4375
CAS No.:833-52-3
- Menisporphine
Catalog No.:BCN7902
CAS No.:83287-02-9
- Napabucasin
Catalog No.:BCC6525
CAS No.:83280-65-3
- Lauryl-LF 11
Catalog No.:BCC6175
CAS No.:832729-14-3
- LF 11
Catalog No.:BCC6174
CAS No.:832729-13-2
- APD668
Catalog No.:BCC5389
CAS No.:832714-46-2
- Angelol H
Catalog No.:BCN8047
CAS No.:83247-73-8
- Dehydrocavidine
Catalog No.:BCN2549
CAS No.:83218-34-2
- 1beta-Hydroxy-beta-eudesmol
Catalog No.:BCN7097
CAS No.:83217-89-4
- ISX 9
Catalog No.:BCC6181
CAS No.:832115-62-5
- Dynorphin B
Catalog No.:BCC5987
CAS No.:83335-41-5
- 10-O-Caffeoyl-6-epiferetoside
Catalog No.:BCN4822
CAS No.:83348-22-5
- 25(R)-Hydroxyprotopanaxadiol
Catalog No.:BCN2493
CAS No.:83349-37-5
- D609
Catalog No.:BCC1509
CAS No.:83373-60-8
- Prenyl caffeate
Catalog No.:BCC8351
CAS No.:100884-13-7
- PL 017
Catalog No.:BCC5864
CAS No.:83397-56-2
- Phenformin HCl
Catalog No.:BCC4362
CAS No.:834-28-6
- ICI 154,129
Catalog No.:BCC5677
CAS No.:83420-94-4
- Boc-D-Prolinol
Catalog No.:BCC2707
CAS No.:83435-58-9
- Ebracteolata cpd B
Catalog No.:BCN3781
CAS No.:83459-37-4
- Ginsenoside Ra1
Catalog No.:BCN8392
CAS No.:83459-41-0
- Mifamurtide
Catalog No.:BCC5241
CAS No.:83461-56-7
Dietary lariciresinol attenuates mammary tumor growth and reduces blood vessel density in human MCF-7 breast cancer xenografts and carcinogen-induced mammary tumors in rats.[Pubmed:18528864]
Int J Cancer. 2008 Sep 1;123(5):1196-204.
Lariciresinol is a dietary lignan that accounts for a significant portion of the total phytoestrogen intake from Western foods. Recent epidemiological studies suggest that high dietary intake of lignans and lariciresinol is associated with reduced breast cancer risk. However, no causal relationship between lariciresinol intake and breast cancer development has been established. In this study, we investigated for the first time the effects and possible mechanisms of action of lariciresinol on hormone responsive mammary cancer in vivo in dimethylbenz[a]anthracene induced mammary cancer in rats, and in human MCF-7 breast cancer xenografts in athymic mice. For tumor bearing rats, lariciresinol (3 or 15 mg/kg of body weight) or vehicle was administered p.o. daily for 9 weeks. For E2-maintained ovariectomized athymic mice bearing orthotopic MCF-7 tumors, control diet (AIN-93G) or lariciresinol containing diet (AIN-93G supplemented with 20 or 100 mg of lariciresinol/kg of diet) was administered for 5 weeks. In both models, lariciresinol administration inhibited the tumor growth and tumor angiogenesis. In MCF-7 cells, enterolactone significantly inhibited the E2-stimulated VEGF secretion. Moreover, in MCF-7 xenografts, lariciresinol administration enhanced tumor cell apoptosis and increased estrogen receptor beta expression. Lariciresinol and its further metabolites secoisolariciresinol, enterodiol and enterolactone were found in serum of both rats and athymic mice confirming a similar lignan metabolism pattern as in humans. These findings indicate conceivable importance of dietary lignan lariciresinol in inhibition of breast cancer development.
(+)-Pinoresinol/(-)-lariciresinol reductase from Linum perenne Himmelszelt involved in the biosynthesis of justicidin B.[Pubmed:17257599]
FEBS Lett. 2007 Feb 20;581(4):603-10.
A cDNA encoding a pinoresinol-lariciresinol reductase PLR (PLR-Lp1) was isolated from a cell culture of Linum perenne Himmelszelt accumulating the arylnaphthalene lignan justicidin B. The recombinant PLR-Lp1 prefers (+)-pinoresinol in the first reaction step, but (-)-Lariciresinol in the second step. Therefore, it is the first PLR described with opposite enantiospecificity within the two reaction steps catalysed by PLRs. Hairy root lines transformed with an ihpRNAi construct to suppress plr gene expression show less mRNA accumulation for the plr-Lp1 gene and PLR enzyme activity. Justicidin B accumulation was reduced down to 24% in comparison to control lines showing the involvement of PLR-Lp1 in the biosynthesis of justicidin B.
